At Orsini Specialty Pharmacy, we provide our patients with both the clinical and administrative support necessary to help manage the treatment of their...
Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition. HAE involves recurring attacks of severe swelling...
Mucopolysaccharidosis (MPS) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of...
This past year has shone a harsh light on some of our healthcare system’s most glaring flaws, illuminating a divide too deep to be ignored. Limited...
We are honored to share the third patient story in our "All the Difference" series, where extraordinary individuals share their experiences living with...
This blog was written by Karen Murphy, Patient Assistance Liaison at Orsini Specialty Pharmacy It’s an unfortunate truth that although incredible...
This blog was written by Mike Fieri, Orsini President and CEO. "All the Difference" is an embodiment of stories from people living with life-changing...
We are honored to share the second eBook in our "All the Difference" series, where extraordinary individuals share their experiences living with rare...
Prior authorization is used by health insurance companies to determine whether they will cover a prescribed procedure, service, or medication for a...
For a pharmaceutical manufacturer, it's essential to find a strategic partner to optimize individual therapies to provide the highest quality clinical...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)